KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Intangibles (2016 - 2025)

Emergent BioSolutions (EBS) has 13 years of Intangibles data on record, last reported at $469.0 million in Q2 2025.

  • For Q2 2025, Intangibles changed N/A year-over-year to $469.0 million; the TTM value through Jun 2025 reached $469.0 million, changed N/A, while the annual FY2024 figure was $501.5 million, 11.49% down from the prior year.
  • Intangibles reached $469.0 million in Q2 2025 per EBS's latest filing, down from $501.5 million in the prior quarter.
  • Across five years, Intangibles topped out at $724.9 million in Q3 2022 and bottomed at $469.0 million in Q2 2025.
  • Average Intangibles over 5 years is $589.1 million, with a median of $604.6 million recorded in 2021.
  • Peak YoY movement for Intangibles: decreased 8.82% in 2021, then decreased 11.49% in 2024.
  • A 5-year view of Intangibles shows it stood at $604.6 million in 2021, then grew by 19.9% to $724.9 million in 2022, then decreased by 21.84% to $566.6 million in 2023, then decreased by 11.49% to $501.5 million in 2024, then fell by 6.48% to $469.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $469.0 million in Q2 2025, $501.5 million in Q4 2024, and $566.6 million in Q4 2023.